Adult Patients | TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.

Adult Patients research study

What is the primary objective of this study?

This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and Romiplostim as bridge therapy for splenectomy in adult patients with primary immune thrombocytopenia.

Who is eligible to participate?

Inclusion Criteria: - Persistent or chronic ITP in symtomatic phase. - 18 years of age or older. - Indication for splenectomy due to refractory response to a previous therapy. - Have used eltrombopag or romiplostim to increase platelet count before splenectomy. - Have undergone splenectomy. Exclusion Criteria: - No informed consent.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Adult Patients

Immune Primary Thrombocytopenia



Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status


Start Date: May 2014

Completed Date: October 2018


Type: Observational


Primary Outcome: Number of patients responding to TPO-mimetics

Secondary Outcome: Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.

Study sponsors, principal investigator, and references

Principal Investigator: Francesco Zaja, Pr.

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto


More information:

Discuss Thrombocytopenia